14/40 (35%) of erythroid‐stimulating agent‐treated patients with SF3B1‐mutated MDS experienced response versus 9/56 (16%) wild‐type patients (p = 0.032)93 showing a preferential response of SF3B1‐mutated patients to ESAs. Here, SF3B1 is linked to myelodysplastic syndrome.